PROFILE AND RISK FACTORS OF ADVERSE REACTIONS IN NEW TUBERCULOSIS CASES RECEIVING TREATMENT
https://doi.org/10.21292/2075-1230-2017-95-6-22-29
Abstract
In order to evaluate the frequency and risk factors of adverse reactions, the monitoring results of clinical and laboratory tests of 435 new cases of respiratory tuberculosis being on the intensive phase of chemotherapy have been analyzed. 95.2% of patients had adverse reactions (95% CI 92.7-96.9); 48.7% demonstrated severe adverse reactions and in 72.7% treatment regimen had to be changed. Regarding the profile of adverse reactions, hepatotoxic ones prevailed (59.3%), they were followed by allergic reactions (53.6%), gastrointestinal reactions (35.6%) and hyperuricemia (61.6%). Certain risk factors have been identified for each of the above types of adverse reactions, making it possible to predict and prevent them prior to the start of chemotherapy.
About the Authors
D. A. Ivаnovа
Moscow Municipal Scientific - Practical Center of Tuberculosis Control, Health Department of Moscow
Russian Federation
Russian Federation
Diana A. Ivanova - Candidate of Medical Sciences, Leading Researcher of Research Clinical Department.
10, Stronymka St., Moscow, 107014,Phone/Fax: +7 (499) 269-14-10; +7 (495) 964-86-37
S. E. Borisov
Moscow Municipal Scientific - Practical Center of Tuberculosis Control, Health Department of Moscow
Russian Federation
Russian Federation
Sergey E. Borisov - Deputy Director for Research and Clinical Activities.
10, Stronymka St., Moscow, 107014, Phone/Fax: 8 (499) 268-00-05, 8 (495) 964-86-37
References
1. Аstakhova А.V., Lepakhin V.K. Lekarstva: neblagopriyantye pobochnye effekty i kontrol bezopasnosti. [Drugs: adverse reactions and safety control]. 2nd ed., Moscow, EKSMO Publ., 2008.
2. Mishin M.Yu, Medikamentoznye oslozhneniya kombinirovannoy khimioterapii tuberkuleza legkikh. [Drug-associated complication of combined chemotherapy of pulmonary tuberculosis]. Moscow, OOO Meditsinskoye informatsionnoye agentstvo Publ., 2007, 248 p.
3. Mordyk А.V., Kondrya А.V., Gaponenko G.E. Frequency of adverse reactions to tuberculosis drugs in new respiratory tuberculosis patients older than 18 years and factors influencing on their development. Tuberculosis and Lung Diseases, 2010, no. 2, pp. 44-48. (In Russ.)
4. Tuberkulez v Rossiyskoy Federatsii 2012, 2013, 2014 g. Аnaliticheskiy obzor statisticheskikh pokazateley, ispolzuemykh v Rossiyskoy Federatsii i v mire. [Tuberculosis in the Russian Federation in 2011, 2013. 2014. Analytic review of statistic rates used in the Russian Federation and in the world]. Moscow, 2015, 312 p.
5. Beydoun M.A., Canas J.A., Beydoun H.A. et al. Serum antioxidant concentrations and metabolic syndrome are associated among U.S. adolescents in recent national surveys. J. Nutr., 2012, vol. 142, no. 9, pp. 1693-1704.
6. Bidell M.R., Lodise T.P. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy, 2016, vol. 36, no. 6, pp. 679-693.
7. Division of Microbiology and Infection Diseases (DMID) adult toxicity table. National Institute of Allergy and Infectious Diseases, Bethesda, 2007. URL: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.pdf (Accesses as of 09.07.2013)
8. Ford E.S., Choi H.K. Associations between concentrations of uric acid with concentrations of vitamin A and beta-carotene among adults in the United States. Nutr. Res., 2013, vol. 33, no. 12, pp. 995-1002.
9. Javadi M.R., Shalviri G., Gholami K. et al. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf., 2007, vol. 16, no. 10, pp. 1104-1110.
10. Kumar A.K., Gurumurthy P. Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs. Indian. J. Exp. Biol., 2004, vol. 42, no. 3, pp. 323-325.
11. Nagayama N., Masuda K., Baba M. et al. Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin. Kekkaku, 2003, vol. 78, no. 4, pp. 339-346.
12. Preventing and minimizing risks associated with antituberculosis medicines to improve patient safety. Management Sciences for Health, Arlington, 2013. URL: http://siapsprogram.org/wp-content/uploads/2014/02/14-033-Min-RiskAnti-TB-Meds-final.pdf. (Accessed as of 18.10.2016)
13. Ramappa V., Aithal G. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J. Clin. and Experimental Hepatology, 2012, vol. 3, no. 1, pp. 37-49.
14. Saukkonen J.J., Cohn D.L., Jasmer R.M. еt al. An official ATS Statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med., 2006, vol. 174, no. 8, pp. 935-952.
15. Shakya R., Rao B., Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann. Pharmacother., 2004, vol. 38, no. 6, pp. 1074-1079.
16. Singla R., Sharma S.K., Mohan A. et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J. Med. Res., 2010, vol. 132, pp. 81-86.
17. Vieira D.E., Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J. Bras. Pneumol., 2008, vol. 34, no. 12, pp. 1049-1055.
18. Zaverucha-do-Valle C., Monteiro S.P., El-Jaick K.B. et al. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis (Edinb.), 2014, vol. 94, no. 3, pp. 299-305.
Review
For citations:
Ivаnovа D.A., Borisov S.E. PROFILE AND RISK FACTORS OF ADVERSE REACTIONS IN NEW TUBERCULOSIS CASES RECEIVING TREATMENT. Tuberculosis and Lung Diseases. 2017;95(6):22-29. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-6-22-29
Views:
1669
Email this article 